Collegium Pharmaceutical’s (COLL) Buy Rating Reiterated at Needham & Company LLC

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reissued by Needham & Company LLC in a research report issued on Wednesday,Benzinga reports. They currently have a $46.00 price target on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price indicates a potential upside of 86.46% from the stock’s previous close.

A number of other research analysts have also issued reports on COLL. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Piper Sandler reduced their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Collegium Pharmaceutical Trading Down 6.4 %

Collegium Pharmaceutical stock opened at $24.67 on Wednesday. Collegium Pharmaceutical has a 1 year low of $23.23 and a 1 year high of $42.29. The firm’s 50-day moving average is $29.23 and its 200-day moving average is $31.67. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company has a market cap of $792.70 million, a P/E ratio of 10.63 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. On average, equities analysts expect that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 10,445 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the completion of the sale, the chief financial officer now owns 165,246 shares of the company’s stock, valued at $4,959,032.46. This represents a 5.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now directly owns 154,204 shares in the company, valued at approximately $4,330,048.32. The trade was a 20.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 81,693 shares of company stock valued at $2,334,994 in the last quarter. Corporate insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its stake in shares of Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after acquiring an additional 175,892 shares during the period. Barclays PLC boosted its stake in Collegium Pharmaceutical by 152.2% during the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock valued at $2,899,000 after purchasing an additional 45,291 shares in the last quarter. Sanctuary Advisors LLC increased its position in shares of Collegium Pharmaceutical by 10.7% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock valued at $695,000 after purchasing an additional 1,731 shares during the period. FMR LLC raised its stake in shares of Collegium Pharmaceutical by 1,532.2% in the 3rd quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock worth $1,459,000 after buying an additional 35,439 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of Collegium Pharmaceutical by 399.4% in the 3rd quarter. Janus Henderson Group PLC now owns 69,485 shares of the specialty pharmaceutical company’s stock worth $2,686,000 after buying an additional 55,572 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.